SAKK 16/14: Adding durvalumab to neoadjuvant chemotherapy achieves encouraging EFS and OS in patients with resectable stage IIIA(N2) NSCLC

Lung, Respiratory and Thoracic Cancer
Do you want to read an article? Please log in or register.